Practice question

Answer the question and get instant feedback.

MediumEndocrinologyType 2 diabetes with ASCVDca-mccqe1ca-ccfpca-rcpsc-im

A 58-year-old man with poorly controlled type 2 diabetes (HbA1c 9.1%) and established coronary artery disease is on maximally tolerated metformin and a sulfonylurea. According to the 2024 Diabetes Canada pharmacotherapy update, which additional agent class is most appropriate to improve cardiovascular and renal outcomes?

Practice more on iatroX

Educational content. Not a substitute for clinical judgement or local policy.